249 related articles for article (PubMed ID: 35255629)
1. Therapeutic Approaches for Cerebrovascular Dysfunction After Aneurysmal Subarachnoid Hemorrhage: An Update and Future Perspectives.
Torregrossa F; Grasso G
World Neurosurg; 2022 Mar; 159():276-287. PubMed ID: 35255629
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage.
Caylor MM; Macdonald RL
Neurocrit Care; 2024 Feb; 40(1):159-169. PubMed ID: 37740138
[TBL] [Abstract][Full Text] [Related]
3. Brain Oxygen-Directed Management of Aneurysmal Subarachnoid Hemorrhage. Temporal Patterns of Cerebral Ischemia During Acute Brain Attack, Early Brain Injury, and Territorial Sonographic Vasospasm.
Narotam PK; Garton A; Morrison J; Nathoo N; Narotam N
World Neurosurg; 2022 Oct; 166():e215-e236. PubMed ID: 35803565
[TBL] [Abstract][Full Text] [Related]
4. Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage.
Daou BJ; Koduri S; Thompson BG; Chaudhary N; Pandey AS
CNS Neurosci Ther; 2019 Oct; 25(10):1096-1112. PubMed ID: 31583833
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Dayyani M; Sadeghirad B; Grotta JC; Zabihyan S; Ahmadvand S; Wang Y; Guyatt GH; Amin-Hanjani S
Stroke; 2022 Jun; 53(6):1993-2005. PubMed ID: 35354302
[TBL] [Abstract][Full Text] [Related]
6. Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study.
Muraoka S; Asai T; Fukui T; Ota S; Shimato S; Koketsu N; Nishizawa T; Araki Y; Saito R
Neurosurg Rev; 2023 Aug; 46(1):195. PubMed ID: 37555872
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal anti-inflammatory drugs in the pathophysiology of vasospasms and delayed cerebral ischemia following subarachnoid hemorrhage: a critical review.
Solar P; Mackerle Z; Joukal M; Jancalek R
Neurosurg Rev; 2021 Apr; 44(2):649-658. PubMed ID: 32124117
[TBL] [Abstract][Full Text] [Related]
8. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients.
Endo H; Hagihara Y; Kimura N; Takizawa K; Niizuma K; Togo O; Tominaga T
J Neurosurg; 2022 Dec; 137(6):1707-1717. PubMed ID: 35364589
[TBL] [Abstract][Full Text] [Related]
9. Update on intrathecal management of cerebral vasospasm: a systematic review and meta-analysis.
Grossen AA; Ernst GL; Bauer AM
Neurosurg Focus; 2022 Mar; 52(3):E10. PubMed ID: 35231885
[TBL] [Abstract][Full Text] [Related]
10. Associations between endothelin polymorphisms and aneurysmal subarachnoid hemorrhage, clinical vasospasm, delayed cerebral ischemia, and functional outcome.
Griessenauer CJ; Starke RM; Foreman PM; Hendrix P; Harrigan MR; Fisher WS; Vyas NA; Lipsky RH; Lin M; Walters BC; Pittet JF; Mathru M
J Neurosurg; 2018 May; 128(5):1311-1317. PubMed ID: 28548598
[TBL] [Abstract][Full Text] [Related]
11. An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage.
Maruhashi T; Higashi Y
Expert Opin Pharmacother; 2021 Aug; 22(12):1601-1614. PubMed ID: 33823726
[No Abstract] [Full Text] [Related]
12. The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Bruder N; Higashida R; Santin-Janin H; Dubois C; Aldrich EF; Marr A; Roux S; Mayer SA
BMC Neurol; 2022 Dec; 22(1):492. PubMed ID: 36539711
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage.
Smetana KS; Buschur PL; Owusu-Guha J; May CC
Crit Care Nurs Q; 2020; 43(2):138-156. PubMed ID: 32084059
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Saber H; Desai A; Palla M; Mohamed W; Seraji-Bozorgzad N; Ibrahim M
J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):2979-2985. PubMed ID: 30093204
[TBL] [Abstract][Full Text] [Related]
15. Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.
Qureshi AI; Lobanova I; Huang W; Ishfaq MF; Broderick JP; Cassarly CN; Martin RH; Macdonald RL; Suarez JI
Neurocrit Care; 2022 Apr; 36(2):662-681. PubMed ID: 34940927
[TBL] [Abstract][Full Text] [Related]
16. Review of aneurysmal subarachnoid hemorrhage--focus on treatment, anesthesia, cerebral vasospasm prophylaxis, and therapy.
Lin BF; Kuo CY; Wu ZF
Acta Anaesthesiol Taiwan; 2014 Jun; 52(2):77-84. PubMed ID: 25016512
[TBL] [Abstract][Full Text] [Related]
17. Biomarker Discovery in Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage.
Przybycien-Szymanska MM; Ashley WW
J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1453-64. PubMed ID: 25957908
[TBL] [Abstract][Full Text] [Related]
18. Early Hydrogen-Oxygen Gas Mixture Inhalation in Patients with Aneurysmal Subarachnoid Hemorrhage (HOMA): study protocol for a randomized controlled trial.
Lin F; Li R; Chen Y; Yang J; Wang K; Jia Y; Han H; Hao Q; Shi G; Wang S; Zhao Y; Chen X
Trials; 2024 Jun; 25(1):377. PubMed ID: 38863026
[TBL] [Abstract][Full Text] [Related]
19. Investigational drugs for vasospasm after subarachnoid hemorrhage.
Tallarico RT; Pizzi MA; Freeman WD
Expert Opin Investig Drugs; 2018 Apr; 27(4):313-324. PubMed ID: 29600883
[TBL] [Abstract][Full Text] [Related]
20. [Protective measures against cerebral ischemia following subarachnoid hemorrhage: Part 1].
Romero Kräuchi O; Verger Bennasar AM
Rev Esp Anestesiol Reanim; 2011 Apr; 58(4):230-5. PubMed ID: 21608279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
